Synaptogenix, Inc. (SNPX)

$7.04

+0.34 (+5.07%)
Rating:
Recommendation:
-
Symbol SNPX
Price $7.04
Beta 0.000
Volume Avg. 0.08M
Market Cap 48.158M
Shares () -
52 Week Range 3.79-14.5
1y Target Est -
DCF Unlevered SNPX DCF ->
DCF Levered SNPX LDCF ->
ROE 25.10% Buy
ROA 26.62% Buy
Operating Margin -
Debt / Equity 2.16% Neutral
P/E -
P/B 1.69 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SNPX news


Healthcare
Biotechnology
NASDAQ Capital Market

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.